Cardiology 2013 (Full reference info)

Reference Type: Journal Article
Record Number: 760Author: Clemmensen, P., Dridi, N. P. and Holmvang, L.
Year: 2013
Title: Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology
Journal: Cardiovasc Drugs Ther
Volume: 27
Issue: 3
Pages: 239-45
Date: Jun
Short Title: Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology
Alternate Journal: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
ISSN: 1573-7241 (Electronic)
0920-3206 (Linking)
DOI: 10.1007/s10557-013-6444-2
Accession Number: 23380983
Keywords: Adenosine/administration & dosage/adverse effects/*analogs &
derivatives/therapeutic use
Cardiovascular Diseases/blood/drug therapy/surgery
Humans
*Percutaneous Coronary Intervention
Piperazines/administration & dosage/adverse effects/*therapeutic use
Platelet Aggregation Inhibitors/administration & dosage/adverse
effects/*therapeutic use
Purinergic P2Y Receptor Antagonists/administration & dosage/adverse
effects/*therapeutic use
Randomized Controlled Trials as Topic
Stents
Thiophenes/administration & dosage/adverse effects/*therapeutic use
Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use
Treatment Outcome
Abstract: For several years, clopidogrel plus aspirin has been the dual antiplatelet therapy (DAPT) of choice for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation. More recently, prasugrel and ticagrelor have demonstrated greater efficacy than clopidogrel. In TRITON-TIMI 38, the risk of TIMI major bleeding unrelated to coronary artery bypass graft (CABG) surgery was similar for prasugrel and clopidogrel after excluding subgroups with increased bleeding risk (previous stroke or transient ischemic event; age >/=75 years; weight Notes: Clemmensen, Peter
Dridi, Nadia Paarup
Holmvang, Lene
eng
Research Support, Non-U.S. Gov’t
Review
2013/02/06 06:00
Cardiovasc Drugs Ther. 2013 Jun;27(3):239-45. doi: 10.1007/s10557-013-6444-2.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23380983
Author Address: Department of Cardiology B, The Heart Centre, Rigshospitalet – Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. peter.clemmensen@regionh.dk

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155